ModeX Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- ModeX Therapeutics's estimated annual revenue is currently $13.5M per year.
- ModeX Therapeutics's estimated revenue per employee is $155,000
Employee Data
- ModeX Therapeutics has 87 Employees.
- ModeX Therapeutics grew their employee count by 67% last year.
ModeX Therapeutics's People
Name | Title | Email/Phone |
---|---|---|
1 | Senior Scientist | Reveal Email/Phone |
ModeX Therapeutics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $12.7M | 82 | -45% | $107.3M | N/A |
#2 | $0.2M | 1 | -50% | N/A | N/A |
#3 | $6.2M | 40 | 21% | N/A | N/A |
#4 | $42.2M | 218 | 4% | $165M | N/A |
#5 | $14.6M | 94 | -37% | $312.8M | N/A |
#6 | $0.3M | 2 | -67% | N/A | N/A |
#7 | $235M | 366 | -5% | $340.9M | N/A |
#8 | $56M | 289 | -7% | $7.6M | N/A |
#9 | $4.7M | 61 | 36% | N/A | N/A |
#10 | $2M | 13 | 8% | N/A | N/A |
What Is ModeX Therapeutics?
ModeX Therapeutics is a clinical-stage biopharmaceutical company developing innovative multispecific biologics for cancer and infectious disease. Its platforms unite the power of multiple biologics in a single molecule to create multispecific antibodies and vaccines with unprecedented versatility and potency in fighting complex disease. The ModeX pipeline includes candidates against both solid and liquid tumors, as well as several of the world’s most pressing viral threats. Its founding team includes globally recognized medical innovators with proven track records of delivering breakthroughs for patients. ModeX is an OPKO Health company based in Natick, Massachusetts.
keywords:N/AN/A
Total Funding
87
Number of Employees
$13.5M
Revenue (est)
67%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $28.3M | 87 | -2% | N/A |
#2 | $7.5M | 95 | -14% | N/A |
#3 | $15.4M | 96 | 17% | N/A |
#4 | $32M | 97 | N/A | N/A |
#5 | $21.2M | 101 | -27% | N/A |